Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer127(12), 2893–2917 (2010).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Thompson Coon J, Rogers G, Hewson P et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol. Assess.11(34), 1–206 (2007).
   PubMed Web of Science ®Google Scholar
• Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology127(5 Suppl. 1), S5–S16 (2004).
   PubMed Web of Science ®Google Scholar
• Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin. Liver Dis.30(1), 3–16 (2010).
   PubMed Web of Science ®Google Scholar
• Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F. EUROCARE working group. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am. J. Gastroenterol.102(8), 1661–1670 (2007).
   PubMed Web of Science ®Google Scholar
• McCracken M, Olsen M, Chen MS Jr et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J. Clin.57(4), 190–205 (2007).
   PubMed Web of Science ®Google Scholar
• Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma – epidemiological trends and risk factors. Dig. Dis.27(2), 80–92 (2009).
   PubMed Web of Science ®Google Scholar
• Amarapurkar D, Han KH, Chan HL, Ueno Y. Asia–Pacific working party on prevention of hepatocellular carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia–Pacific region. J. Gastroenterol. Hepatol.24(6), 955–961 (2009).
   PubMedGoogle Scholar
• Poon D, Anderson BO, Chen LT et al. Asian oncology summit. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian oncology summit 2009. Lancet Oncol.10(11), 1111–1118 (2009).
   PubMed Web of Science ®Google Scholar
• Shariff MI, Cox IJ, Gomaa AI et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev. Gastroenterol. Hepatol.3(4), 353–367 (2009).
   PubMedGoogle Scholar
• Cabibbo G, Craxì A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur. Rev. Med. Pharmacol. Sci.14(4), 352–355 (2010).
   PubMed Web of Science ®Google Scholar
• Tiribelli C, Melato M, Crocè LS, Giarelli L, Okuda K, Ohnishi K. Prevalence of hepatocellular carcinoma and relation to cirrhosis: comparison of two different cities of the world – Trieste, Italy, and Chiba, Japan. Hepatology10(6), 998–1002 (1989).
   PubMed Web of Science ®Google Scholar
• Colombo M. The role of hepatitis C virus in hepatocellular carcinoma. Recent Results Cancer Res.154, 337–344 (1998).
   PubMedGoogle Scholar
• Andrisani OM, Barnabas S. The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis (review). Int. J. Oncol.15(2), 373–379 (1999).
   PubMed Web of Science ®Google Scholar
• Ho SB, Groessl E, Dollarhide A, Robinson S, Kravetz D, Dieperink E. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am. J. Gastroenterol.103(7), 1810–1823 (2008).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet362(9399), 1907–1917 (2003).
   PubMed Web of Science ®Google Scholar
• Schwartz ME, Sung M, Mor E et al. A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J. Am. Coll. Surg.180(5), 596–603 (1995).
   PubMedGoogle Scholar
• Van Cleave J, Devine P, Odom-Ball P. Multidisciplinary care of hepatocellular carcinoma. Cancer Pract.7(6), 302–308 (1999).
   PubMedGoogle Scholar
• Rilling WS, Drooz A. Multidisciplinary management of hepatocellular carcinoma. J. Vasc. Interv. Radiol.13(9 Pt 2), S259–S263 (2002).
   Google Scholar
• Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis.30(1), 61–74 (2010).
   PubMed Web of Science ®Google Scholar
• Gish RG, Marrero JA, Benson AB. A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol. Hepatol. (NY)6(3 Suppl. 6), 1–16 (2010).
   Google Scholar
• Chan AC, Poon RT, Ng KK, Lo CM, Fan ST, Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann. Surg.247(4), 666–673 (2008).
   PubMedGoogle Scholar
• Taylor C, Munro AJ, Glynne-Jones R et al. Multidisciplinary team working in cancer: what is the evidence? BMJ340, c951 (2010).
   PubMed Web of Science ®Google Scholar
• Fennell ML, Das IP, Clauser S, Petrelli N, Salner A. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. J. Natl Cancer Inst. Monogr.2010(40), 72–80 (2010).
   PubMedGoogle Scholar
• Chang TT, Sawhney R, Monto A et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford)10(6), 405–411 (2008).
   PubMedGoogle Scholar
• Verslype C, Van Cutsem E, Dicato M et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on gastrointestinal cancer, Barcelona, 2008. Ann. Oncol.20(Suppl. 7), vii1–vii6 (2009).
   PubMedGoogle Scholar
• Bruix J, Sherman M. Practice guidelines committee, American association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology42(5), 1208–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J et al. Panel of experts in HCC-design clinical trials. Design and end points of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst.100(10), 698–711 (2008).
   PubMed Web of Science ®Google Scholar
• Martin RC II, Jarnagin WR. Randomized clinical trials in hepatocellular carcinoma and biliary cancer. Surg. Oncol. Clin. N. Am.11(1), 193–205 (2002).
   PubMedGoogle Scholar
• Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. Aliment Pharmacol. Ther.23(11), 1535–1547 (2006).
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Imamura H, Matsuyama Y et al. AFP, AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J. Gastroenterol.45(12), 1272–1282 (2010).
   PubMed Web of Science ®Google Scholar
• Beppu T, Sugimoto K, Shiraki K et al. Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation. Int. J. Mol. Med.26(3), 425–433 (2010).
   PubMedGoogle Scholar
• Zhang XF, Lai EC, Kang XY et al.Lens culinaris agglutinin-reactive fraction of α-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection. Ann. Surg. Oncol.18(8), 2218–2223 (2011).
   PubMed Web of Science ®Google Scholar
• Yamashiki N, Sugawara Y, Tamura S et al. Diagnostic accuracy of α-fetoprotein and des-γ-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates. Hepatol. Res.41(12), 1199–1207 (2011).
   PubMedGoogle Scholar
• Sterling RK, Wright EC, Morgan TR et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am. J. Gastroenterol.107(1), 64–74 (2012).
   PubMed Web of Science ®Google Scholar
• Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett.242(2), 151–167 (2006).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S et al. Phase 2 study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.24(26), 4293–4300 (2006).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. SHARP investigators study group. Sorafenib in advanced hepatocellular carcinoma. N. Engl J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a Phase 3 randomised, double-blind, placebo-controlled trial. Lancet Oncol.10(1), 25–34 (2009).
   PubMed Web of Science ®Google Scholar
• Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs69(2), 223–240 (2009).
   PubMed Web of Science ®Google Scholar
• Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev. Anticancer Ther.9(6), 739–745 (2009).
   PubMed Web of Science ®Google Scholar
• Siegel AB, Olsen SK, Magun A, Brown RS Jr. Sorafenib: where do we go from here? Hepatology52(1), 360–369 (2010).
   PubMedGoogle Scholar
• Zhu AX. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. Expert Opin. Investig. Drugs19(5), 663–672 (2010).
   PubMed Web of Science ®Google Scholar
• Donckier V, Van Laethem JL, Van Gansbeke D et al. New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patients. J. Surg. Oncol.84(1), 36–44 (2003).
   PubMedGoogle Scholar
• Wei AC, Tung-Ping Poon R, Fan ST, Wong J. Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br. J. Surg.90(1), 33–41 (2003).
   PubMedGoogle Scholar
• Laurent A, Cherqui D, Lesurtel M, Brunetti F, Tayar C, Fagniez PL. Laparoscopic liver resection for subcapsular hepatocellular carcinoma complicating chronic liver disease. Arch. Surg.138(7), 763–769 (2003).
   PubMedGoogle Scholar
• Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med.334(11), 693–699 (1996).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis.19(3), 329–338 (1999).
   PubMed Web of Science ®Google Scholar
• Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol. Int.4(1), 396–405 (2009).
   PubMedGoogle Scholar
• Changchien CS, Chen CL, Yen YH et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J. Gastroenterol.43(2), 159–170 (2008).
   PubMed Web of Science ®Google Scholar
• A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology28(3), 751–755 (1998).
   PubMed Web of Science ®Google Scholar
• Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology31(4), 840–845 (2000).
   PubMed Web of Science ®Google Scholar
• Leung TW, Tang AM, Zee B et al. Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer94(6), 1760–1769 (2002).
   PubMed Web of Science ®Google Scholar
• Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol.38(3), 207–215 (2003).
   PubMed Web of Science ®Google Scholar
• Kudo M, Chung H, Haji S et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology40(6), 1396–1405 (2004).
   PubMedGoogle Scholar
• Nathan H, Bridges JF, Schulick RD et al. Understanding surgical decision making in early hepatocellular carcinoma. J. Clin. Oncol.29(6), 619–625 (2011).
   PubMedGoogle Scholar
• Mazzaferro V, Llovet JM, Miceli R et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol.10(1), 35–43 (2009).
   PubMed Web of Science ®Google Scholar
• Borentain P, Gregoire E, Hardwigsen J et al. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol.35(3), 234–236 (2011).
   PubMedGoogle Scholar
• Palma LD. Diagnostic imaging and interventional therapy of hepatocellular carcinoma. Br. J. Radiol.71(848), 808–818 (1998).
   PubMed Web of Science ®Google Scholar
• Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment. Pharmacol. Ther.31(4), 461–476 (2010).
   PubMed Web of Science ®Google Scholar
• Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev. Anticancer Ther.10(4), 507–519 (2010).
   PubMed Web of Science ®Google Scholar
• Livraghi T, Meloni F. Treatment of hepatocellular carcinoma by percutaneous interventional methods. Hepatogastroenterology49(43), 62–71 (2002).
   PubMedGoogle Scholar
• Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann. Surg. Oncol.10(1), 52–58 (2003).
   PubMed Web of Science ®Google Scholar
• Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J.14(2), 117–122 (2008).
   PubMed Web of Science ®Google Scholar
• Vilana R, Bruix J, Bru C, Ayuso C, Solé M, Rodés J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology16(2), 353–357 (1992).
   PubMed Web of Science ®Google Scholar
• Yin XY, Xie XY, Lu MD et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer115(9), 1914–1923 (2009).
   PubMed Web of Science ®Google Scholar
• Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology52(2), 762–773 (2010).
   PubMed Web of Science ®Google Scholar
• McWilliams JP, Yamamoto S, Raman SS et al. Percutaneous ablation of hepatocellular carcinoma: current status. J. Vasc. Interv. Radiol.21(Suppl. 8), S204–S213 (2010).
   PubMed Web of Science ®Google Scholar
• Lencioni R, Crocetti L. A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma. Clin. Liver Dis.9(2), 301–314 (2005).
   PubMedGoogle Scholar
• Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J. Clin. Oncol.25(8), 978–986 (2007).
   PubMed Web of Science ®Google Scholar
• Chou CH, Chen PJ, Lee PH, Cheng AL, Hsu HC, Cheng JC. Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells. Clin. Cancer Res.13(3), 851–857 (2007).
   PubMed Web of Science ®Google Scholar
• Cheng LF, Ma KF, Fan WC, Yung AW, Li TM, Wong CS. Hepatocellular carcinoma with extrahepatic collateral arterial supply. J. Med. Imaging Radiat. Oncol.54(1), 26–34 (2010).
   PubMedGoogle Scholar
• Salem R, Hunter RD. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review. Int. J. Radiat. Oncol. Biol. Phys.66(Suppl. 2), S83–S88 (2006).
   PubMed Web of Science ®Google Scholar
• Boucher E, Garin E, Guylligomarc’h A, Olivié D, Boudjema K, Raoul JL. Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. Radiother. Oncol.82(1), 76–82 (2007).
   PubMedGoogle Scholar
• Kojiro M. Pathology. In: Diagnosis and Treatment of Hepatocellular Carcinoma. Livraghi T, Makuuchi M, Buscarini L (Eds). Greenwich Medical Media, London, UK, 27–34 (1997).
   Google Scholar
• Frau M, Biasi F, Feo F, Pascale RM. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol. Aspects Med.31(2), 179–193 (2010).
   PubMed Web of Science ®Google Scholar
• Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int.25(2), 261–265 (2005).
   PubMedGoogle Scholar
• Guan YS, Liu Y. Interventional treatments for hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int.5(4), 495–500 (2006).
   PubMedGoogle Scholar
• Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur. J. Surg. Oncol.31(4), 331–347 (2005).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Majno P. Principles for the best multidisciplinary meetings. Lancet Oncol.12(4), 323–325 (2011).
   PubMedGoogle Scholar